Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by themagicboxon Nov 13, 2020 9:38am

136 Views

Post# 31894239

RE:RE:RE:RE:Risky and burning cash

$340k in 6 months is actually not bad for the Cita cash burn. Was expecting it to be much worse.

MrMugsy wrote: On the cash side, it is also very important for people to understand the company has planned for part of the recent offering to be used for various purposes. The cash position is probably right on the money in terms of how they are planning on spending it.

To recap, from the prospectus ...

1. FDA regulatory consulting - $400K
2. Euro regulatory consulting - $375K
3. Market opportunity studies - $1MM
4. IND-opening study - $300K
5. Reporductive toxicity study - $1.8MM
6. Animal toxicity studies - $3MM
7. Carcinogenicity studies - $2.5MM
8. Phase 3 drug supply - $1.4MM

Items 6-8 requires almost $7M alone.

Then we have Phase 3 Study costs on top of that ... and the latest offering covers $5M of the $50M required. I'm guessing that's related to the dose determing portion. As per the prospectus ... future partner(s) or when funds become available (to cover the rest).

Important to keep in mind that the money has a purpose and it is part of the plan.

Good Luck Longs !!!